Ablatus Therapeutics is an NHS spin-out developing a novel radiofrequency ablation system for the treatment of solid tumours.
|Address:||Babraham Research Campus, Cambridge|
|Membership type:||Professional Individual and Corporate < 5 (£50+VAT pa)|
Our mission is to bring to market Bimodal Electric Tissue Ablation (BETA), an innovative improvement over existing tissue ablation techniques, in order to offer greater clinical options and to improve patient outcomes.
The Company was founded in October 2015 and is the first spin-out from the Norfolk and Norwich University Hospital, where the BETA technology was invented. BETA is a form of tissue ablation – a minimally-invasive procedure whereby abnormal tissues (such as tumours) can be destroyed in situ, as an alternative to surgery. RFA has limitations in terms of the size of tumours it can address, but BETA has the potential to improve upon these, potentially allowing the ablation of previously untreatable tumours.